<DOC>
	<DOCNO>NCT00002621</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial study effectiveness interferon alfa treat child HIV-related cancer include leukemia , non-Hodgkin 's lymphoma , CNS lymphoma , solid tumor .</brief_summary>
	<brief_title>Interferon Alfa Treating Children With HIV-Related Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete response rate one-year disease free survival pediatric patient HIV-related malignancy treat interferon alfa . - Determine toxicity interferon alfa alone combination antiretroviral therapy patient . OUTLINE : - Induction : Patients receive interferon alfa subcutaneously ( SC ) daily day 1-14 . Patients advanced stage III IV undifferentiated lymphomas B-cell acute lymphoblastic leukemia also receive hydrocortisone intrathecally ( IT ) combine cytarabine IT day 14 . - Maintenance : Patients stable respond disease completion induction receive interferon alfa SC 3 time week begin week 1 . Treatment continue minimum 4-12 week absence disease progression unacceptable toxicity . Patients receive IT therapy induction receive IT therapy 4 , 8 , 12 week every 8 week thereafter . Patients follow every 6 month 4 year annually survival entry another POG protocol . PROJECTED ACCRUAL : A total 14-30 evaluable patient accrue study within 4.2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven malignancy diagnose time follow confirmation HIVpositivity , include follow : Leukemia NonHodgkin 's lymphoma CNS lymphoma Other solid tumor Measurable disease Concurrent registration protocol POG9182 require Confirmed HIVpositive POG9182 criterion Required biology study complete PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : More 4 week Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 ( unless bone marrow involvement present ) Hepatic : See Disease Characteristics Bilirubin less 1.5 time normal SGPT SGOT less 2 time normal ( may discuss Study Coordinator ) Renal : Creatinine le 1.5 mg/dL Cardiovascular : Adequate cardiac function echocardiogram/MUGA scan Other : Chronically infected patient must stable enough meet life expectancy requirement PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon cancer Prior interferon alfa viral infection ( i.e. , hepatitis ) must discuss Study Coordinator Chemotherapy : At least 1 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 1 week since prior radiotherapy Surgery : Not specify Other : Prior antiretroviral therapy allow At least 1 week since prior acute treatment serious lifethreatening infection No concurrent local treatment unless discuss Study Coordinator No concurrent acute treatment serious lifethreatening infection Concurrent antiretroviral therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
</DOC>